FR2938188A1 - Composition cosmetique topique apte a regenerer la peau - Google Patents
Composition cosmetique topique apte a regenerer la peau Download PDFInfo
- Publication number
- FR2938188A1 FR2938188A1 FR0857647A FR0857647A FR2938188A1 FR 2938188 A1 FR2938188 A1 FR 2938188A1 FR 0857647 A FR0857647 A FR 0857647A FR 0857647 A FR0857647 A FR 0857647A FR 2938188 A1 FR2938188 A1 FR 2938188A1
- Authority
- FR
- France
- Prior art keywords
- cosmetic composition
- extract
- ginkgo biloba
- magnesium salt
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 title claims abstract description 14
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 239000002537 cosmetic Substances 0.000 title claims abstract description 14
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 title claims abstract description 13
- 239000000284 extract Substances 0.000 title claims abstract description 10
- 159000000003 magnesium salts Chemical class 0.000 title claims abstract description 10
- 230000000699 topical effect Effects 0.000 title claims abstract description 7
- 235000008100 Ginkgo biloba Nutrition 0.000 title abstract description 6
- 244000194101 Ginkgo biloba Species 0.000 title abstract description 6
- 230000001172 regenerating effect Effects 0.000 title description 4
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 6
- 229940068052 ginkgo biloba extract Drugs 0.000 claims description 6
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims description 6
- 229940011399 escin Drugs 0.000 claims description 4
- 229930186222 escin Natural products 0.000 claims description 4
- 229960001983 magnesium aspartate Drugs 0.000 claims description 3
- RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical group [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 claims description 3
- 230000002407 ATP formation Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 7
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- -1 ISOHEXADECANE PROPYLENE GLYCOL Chemical compound 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- HMFHBZSHGGEWLO-AIHAYLRMSA-N alpha-D-ribose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-AIHAYLRMSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960003993 chlorphenesin Drugs 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 230000036540 impulse transmission Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940100458 steareth-21 Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Emergency Medicine (AREA)
- Medical Informatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims (1)
- REVENDICATIONS1/ Composition cosmétique topique contenant du ribose, caractérisée en ce qu'elle contient en outre, en combinaison, un sel de magnésium et un extrait de ginkgo biloba. 2/ Composition cosmétique selon la revendication 1, caractérisée en ce que le ribose représente entre 0,01 et 1%, avantageusement de 0,05% à 0,5% en poids de la composition. 10 3/ Composition cosmétique selon la revendication 1, caractérisée en ce que le sel de magnésium est de l'aspartate de magnésium. 4/ Composition cosmétique selon la revendication 1, caractérisée en ce que le sel de magnésium représente entre 0,001 et 0,5%, avantageusement de 0,05% à 0,1% en poids 15 de la composition. 5/ Composition cosmétique selon la revendication 1, caractérisée en ce que l'extrait de ginkgo biloba est un extrait de feuilles. 20 6/ Composition cosmétique selon la revendication 1, caractérisée en ce que l'extrait de ginkgo biloba représente entre 0,01 et 2 %, avantageusement de l'ordre de 0,1% en poids de la composition. 7/ Composition cosmétique selon la revendication 1, caractérisée en ce qu'elle contient 25 en outre de l'escine. 8/ Composition cosmétique selon la revendication 7, caractérisée en ce que l'escine représente entre 0,1 et 2% en poids de la composition. 30
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0857647A FR2938188B1 (fr) | 2008-11-12 | 2008-11-12 | Composition cosmetique topique apte a regenerer la peau |
ITMI2009A001953A IT1396219B1 (it) | 2008-11-12 | 2009-11-09 | Composizione cosmetica topica atta a rigenerare la pelle |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0857647A FR2938188B1 (fr) | 2008-11-12 | 2008-11-12 | Composition cosmetique topique apte a regenerer la peau |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2938188A1 true FR2938188A1 (fr) | 2010-05-14 |
FR2938188B1 FR2938188B1 (fr) | 2010-11-19 |
Family
ID=40937542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR0857647A Active FR2938188B1 (fr) | 2008-11-12 | 2008-11-12 | Composition cosmetique topique apte a regenerer la peau |
Country Status (2)
Country | Link |
---|---|
FR (1) | FR2938188B1 (fr) |
IT (1) | IT1396219B1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10660838B2 (en) | 2017-06-23 | 2020-05-26 | The Procter & Gamble Company | Composition and method for improving the appearance of skin |
US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
US11583488B2 (en) | 2020-06-01 | 2023-02-21 | The Procter & Gamble Company | Method of improving penetration of a vitamin B3 compound into skin |
US11622963B2 (en) | 2018-07-03 | 2023-04-11 | The Procter & Gamble Company | Method of treating a skin condition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1543823A1 (fr) * | 2003-12-19 | 2005-06-22 | Johnson & Johnson Consumer France SAS | Compositions cosmétiques contenant un extrait de gingko pour l'amélioration de la radiance de la peau |
EP1745789A1 (fr) * | 1998-06-19 | 2007-01-24 | Bioenergy Inc. | Compositions contenants ribose pour élever l'energie in vivo |
-
2008
- 2008-11-12 FR FR0857647A patent/FR2938188B1/fr active Active
-
2009
- 2009-11-09 IT ITMI2009A001953A patent/IT1396219B1/it active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1745789A1 (fr) * | 1998-06-19 | 2007-01-24 | Bioenergy Inc. | Compositions contenants ribose pour élever l'energie in vivo |
EP1543823A1 (fr) * | 2003-12-19 | 2005-06-22 | Johnson & Johnson Consumer France SAS | Compositions cosmétiques contenant un extrait de gingko pour l'amélioration de la radiance de la peau |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10660838B2 (en) | 2017-06-23 | 2020-05-26 | The Procter & Gamble Company | Composition and method for improving the appearance of skin |
US11110049B2 (en) | 2017-06-23 | 2021-09-07 | The Procter & Gamble Company | Composition and method for improving the appearance of skin |
US11622963B2 (en) | 2018-07-03 | 2023-04-11 | The Procter & Gamble Company | Method of treating a skin condition |
US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
US11583488B2 (en) | 2020-06-01 | 2023-02-21 | The Procter & Gamble Company | Method of improving penetration of a vitamin B3 compound into skin |
US11911498B2 (en) | 2020-06-01 | 2024-02-27 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
Also Published As
Publication number | Publication date |
---|---|
FR2938188B1 (fr) | 2010-11-19 |
IT1396219B1 (it) | 2012-11-16 |
ITMI20091953A1 (it) | 2010-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2694692A1 (fr) | Préparation cosmétique de nutrition de la peau. | |
WO1999016415A1 (fr) | Utilisation de l'acide ellagique et de ses derives en cosmetique et en dermatologie | |
CA2266796A1 (fr) | Utilisation d'au moins un hydroxystilbene dans une composition raffermissante | |
EP1039878A1 (fr) | Composition cosmetique contenant au moins une auxine et son utilisation | |
FR2906719A1 (fr) | Utilisation de substances agissant sur le derme papillaire pour leur action anti-age. | |
FR2991166A1 (fr) | Principes actifs activateurs de la mitophagie des cellules cutanees et utilisation pour ameliorer l'etat de la peau | |
EP0938891A1 (fr) | Composition cosmétique contenant de l'acide cinnamique ou de ses dérivés et son utilisation | |
WO2008000974A2 (fr) | Composition cosmetique a base d'acide gras polyinsatures et ses utilisations | |
FR2938188A1 (fr) | Composition cosmetique topique apte a regenerer la peau | |
FR2817748A1 (fr) | Composition cosmetique et/ou dermatologique contenant un extrait d'artemia salina | |
EP1743628A1 (fr) | Composition cosmétique comprenant un extrait d'algue rouge comprenant une association de floridoside et d'acide iséthionique. | |
CA2908535A1 (fr) | Applications cosmetiques et pharmaceutiques de lactobacillus pentosus | |
EP2763652B1 (fr) | Utilisation de glucanes obtenus a partir de prunus persica comme agent cosmetique anti-age | |
CA2255226C (fr) | Utilisation de l'acide cinnamique ou d'au moins l'un de ses derives dans une composition cosmetique | |
FR2844198A1 (fr) | Utilisation d'un activeur de protectin pour ameliorer la resistance de la peau, composition contenant de tels activateurs et procede de selection | |
WO2007036667A1 (fr) | Utilisation du fer sous forme d'un extrait de pierre comme stimulant de la synthese du collagene par les fibroblastes cutanes | |
FR2924023A1 (fr) | Utilisation d'un extrait d'aloe pour la promotion et le renfort de la cohesion des cellules de la peau | |
FR2911278A1 (fr) | Procede d'obtention d'un actif cosmetique depigmentant, principe actif obtenu et compositions l'incluant | |
FR2926461A1 (fr) | Nouveau facteur de croissance cellulaire d'origine non animale et applications | |
EP2381939A1 (fr) | Compositions cosmetiques comprenant des derives d'acide cetogluconique | |
FR2889948A1 (fr) | Composition cosmetique destinee a corriger, maintenir et ameliorer l'hydratation de la peau | |
WO2009056773A2 (fr) | Utilisation cosmetique d'un extrait de cicer arietinum, principe actif, procede d'obtention et compositions | |
FR2914858A1 (fr) | Composition cosmetique | |
FR2945444A1 (fr) | Utilisation cosmetique d'actifs pour ameliorer et/ou reparer la fonction barriere de la peau. | |
WO2023186353A1 (fr) | Dextrines hyperbranchees pour leur utilisation topique pour la prevention ou le traitement d'au moins un symptome de l'inflammation cutanee |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 8 |
|
PLFP | Fee payment |
Year of fee payment: 9 |
|
PLFP | Fee payment |
Year of fee payment: 10 |
|
PLFP | Fee payment |
Year of fee payment: 12 |
|
PLFP | Fee payment |
Year of fee payment: 13 |
|
PLFP | Fee payment |
Year of fee payment: 14 |
|
PLFP | Fee payment |
Year of fee payment: 15 |
|
AU | Other action affecting the ownership or exploitation of an industrial property right |
Effective date: 20231016 |
|
CL | Concession to grant licences |
Name of requester: NAOS, FR Effective date: 20231016 Name of requester: NAOS INSTITUTE OF LIFE SCIENCE, FR Effective date: 20231016 |
|
PLFP | Fee payment |
Year of fee payment: 16 |